2. Search Result
Search Result
Results for "

spondylitis

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Inhibitory Antibodies

1

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99280
    Bimekizumab
    1 Publications Verification

    CDP4940; UCB-4940

    		 Interleukin Related Inflammation/Immunology
    Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
    Bimekizumab
  • HY-15826
    SGC-CBP30
    Maximum Cited Publications
    20 Publications Verification

    		 Epigenetic Reader Domain Histone Acetyltransferase Inflammation/Immunology Cancer
    SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
    SGC-CBP30
  • HY-P9927
    Secukinumab
    5+ Cited Publications

    AIN457

    		 Interleukin Related Inflammation/Immunology Cancer
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
    Secukinumab
  • HY-177129
    Simepdekinra

    LY4100511; DC-853

    		 Interleukin Related Inflammation/Immunology
    Simepdekinra (LY4100511; DC-853) is an IL-17A antagonist. Simepdekinra can be used in the research of moderate to severe plaque-type psoriasis .
    Simepdekinra
  • HY-B1138
    Fenbufen
    1 Publications Verification

    CL-82204

    		 COX Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor .
    Fenbufen
  • HY-153780
    Navepdekinra

    DC-806; LY4100504; S-011806

    		 Interleukin Related Inflammation/Immunology
    Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis .
    Navepdekinra
  • HY-P99754
    Netakimab

    BCD-085

    		 Interleukin Related Infection Inflammation/Immunology
    Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab
  • HY-B0634
    Aceclofenac
    1 Publications Verification

    		 COX Inflammation/Immunology
    Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .
    Aceclofenac
  • HY-B0230
    Phenylbutazone
    3 Publications Verification

    		 COX Inflammation/Immunology
    Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .
    Phenylbutazone
  • HY-P99335
    Vunakizumab

    Anti-Human IL17A Recombinant Antibody; SHR-1314

    		 Interleukin Related Inflammation/Immunology
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .
    Vunakizumab
  • HY-W009706
    Alclofenac

    Allopydin; W-7320

    		 Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    Alclofenac (Allopydin) is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .
    Alclofenac
  • HY-78985
    Benzene-1,3,5-tricarboxylic acid

    Trimesic acid

    		 MOFs Biochemical Assay Reagents Others
    Benzene-1,3,5-tricarboxylic acid (Trimesic acid) is a rigid planar small-molecule scaffold and crosslinker. Benzene-1,3,5-tricarboxylic acid induces bicyclic peptides to adopt a planar conformation, so as to maximize surface area and bind to the flat protein surfaces involved in protein-protein interactions. Benzene-1,3,5-tricarboxylic acid forms ionic crosslinks, hydrogen bonds and π-π bonds with chitosan, thereby constructing a hydrogel network. Benzene-1,3,5-tricarboxylic acid endows chitosan hydrogel systems with specific mechanical properties, enabling sustained release of cancer therapeutic drugs including 5-Fluorouracil (HY-90006) .
    Benzene-1,3,5-tricarboxylic acid
  • HY-P99652
    Gumokimab

    AK 111

    		 Interleukin Related Inflammation/Immunology
    Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
    Gumokimab
  • HY-N7700A
    Guluronic acid sodium
    1 Publications Verification

    G2013 sodium

    		 VEGFR Toll-like Receptor (TLR) COX NO Synthase NF-κB MMP Inflammation/Immunology Cancer
    Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases .
    Guluronic acid sodium
  • HY-N7700
    Guluronic acid

    G2013

    		 MMP COX VEGFR Toll-like Receptor (TLR) NF-κB NO Synthase Inflammation/Immunology Cancer
    Guluronic acid (G2013) is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases .
    Guluronic acid
  • HY-109143B
    (R)-Elsubrutinib

    (R)-ABBV-105

    		 Btk Inflammation/Immunology Cancer
    (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .
    (R)-Elsubrutinib
  • HY-B0230S
    Phenylbutazone(diphenyl-d10)

    		COX Inflammation/Immunology
    Phenylbutazone(diphenyl-d10) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .
    Phenylbutazone(diphenyl-d10)
  • HY-P991682
    Emzotamig

    		TNF Receptor Inflammation/Immunology
    Emzotamig is a monoclonal antibody inhibitor targeting tumor necrosis factor (TNF). Emzotamig is promising for research of autoimmune diseases associated with TNF overexpression, such as rheumatoid arthritis and ankylosing spondylitis .
    Emzotamig
  • HY-B0230S2
    Phenylbutazone-13C12

    		COX Inflammation/Immunology
    Phenylbutazone- 13C12 is the 13C12 labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research.
    Phenylbutazone-13C12
  • HY-127150
    Clofezone

    Perclusone

    		 Collagen Inflammation/Immunology
    Clofezone (Perclusone) is an antirheumatic agent that inhibits collagen formation in rat Chondrus granulomas. Clofezone can be used in the study of various rheumatic diseases, especially arthritis (RA) and ankylosing spondylitis (AS) .
    Clofezone
  • HY-158159
    IL17A-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-B0230R
    Phenylbutazone (Standard)

    		Reference Standards COX Inflammation/Immunology
    Phenylbutazone (Standard) is the analytical standard of Phenylbutazone. This product is intended for research and analytical applications. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .
    Phenylbutazone (Standard)
  • HY-12385
    Ximoprofen

    		TNF Receptor Inflammation/Immunology
    Ximoprofen is a propionic nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory property. Ximoprofen can be used for ankylosing spondylitis research .
    Ximoprofen
  • HY-141535A
    IL-17 modulator 1 disodium

    		Interleukin Related Infection Inflammation/Immunology
    IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
    IL-17 modulator 1 disodium
  • HY-B0634R
    Aceclofenac (Standard)

    		Reference Standards COX Inflammation/Immunology
    Aceclofenac (Standard) is the analytical standard of Aceclofenac. This product is intended for research and analytical applications. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .
    Aceclofenac (Standard)
  • HY-141535
    IL-17 modulator 1

    		Interleukin Related Infection Inflammation/Immunology
    IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
    IL-17 modulator 1
  • HY-B0634S
    Aceclofenac-d4

    		Isotope-Labeled Compounds COX Inflammation/Immunology
    Aceclofenac-d4 is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .
    Aceclofenac-d4
  • HY-W009706A
    Alclofenac sodium

    Allopydin sodium; W-7320 sodium

    		 Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    Alclofenac (Allopydin) sodium is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac sodium irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .
    Alclofenac sodium
  • HY-W009706B
    Alclofenac (lysinate)

    Allopydin (lysinate); W-7320 (lysinate)

    		 Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    Alclofenac (Allopydin) lysinate is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac lysinate irreversibly inhibits platelet aggregation. Alclofenac lysinate can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .
    Alclofenac (lysinate)
  • HY-133976
    Aceclofenac methyl ester

    		Drug Intermediate Neurological Disease Inflammation/Immunology
    Aceclofenac methyl ester (Impurity-D) is the impurity found during the Aceclofenac (HY-B0634). Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID) with analgesic and anti-inflammatory properties .
    Aceclofenac methyl ester
  • HY-B0230S1
    Phenylbutazone-d9

    		Isotope-Labeled Compounds COX Inflammation/Immunology
    Phenylbutazone-d9 is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .
    Phenylbutazone-d9
  • HY-B1138R
    Fenbufen (Standard)

    CL-82204 (Standard)

    		 Reference Standards COX Caspase Inflammation/Immunology
    Fenbufen (Standard) is the analytical standard of Fenbufen. This product is intended for research and analytical applications. Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor .
    Fenbufen (Standard)
  • HY-157139
    ALP/Carbonic anhydrase-IN-1

    		Carbonic Anhydrase Phosphatase Inflammation/Immunology
    ALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonic anhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
    ALP/Carbonic anhydrase-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: